Indevus Pharmaceuticals of Lexington, Massachusetts, has launched a Phase III study of Sanctura XR for overactive bladder, triggering a $10 million milestone payment from Esprit Pharma. An NDA for Sanctura is worth another $10 million with a $25 million payoff waiting for federal approval.
- read this report from Mass High Tech for more